Nephrology and Hypertension Peer Reviewers
Nada Alachkar, MD
Associate Professor of Medicine, Division of Nephrology
The Johns Hopkins University School of Medicine
Disclosure: Grant/Research/Clinical Trial Support: Terumo BCT [suPAR in FSGS (Plasma exchange innovation)].
Michael Allon, MD
Professor of Medicine
University of Alabama at Birmingham
Disclosure: Consultant/Advisory Boards: Cormedix [Dialysis catheter infections (nonantibiotic antimicrobial solution)].
Anatole Besarab, MD
Professor of Medicine
West Virginia University School of Medicine
Disclosure: Consultant/Advisory Boards: VascAlert [Vascular access for hemodialysis (Surveillance technique)]. Employment: Fibrogen [Anemia of CKD (Roxadustat)] - No relevant conflict on topic.
Daniel G Bichet, MD
Professor of Medicine
Universite de Montreal
Disclosure: Grant/Research/Clinical Trial Support: Otsuka Pharmaceuticals [ADPKD (Tolvaptan)]. Speaker's Bureau: Otsuka Pharmaceuticals [ADPKD (Tolvaptan)]. Consultant/Advisory Boards: Otsuka Pharmaceuticals [ADPKD (Tolvaptan)].
Roy D Bloom, MD
Professor of Medicine
University of Pennsylvania
Disclosure: Grant/Research/Clinical Trial Support: Veloxis Pharmaceuticals [Immunosuppression (Tacrolimus)]; Care DX [Diagnostics (DNA blood test)]. Consultant/Advisory Boards: Abbvie [Hepatitis C (Ombitasvir, paritaprevir, ritonavir, plus dasabuvir)]; Merck [Hepatitis C (Elbasvir and grazoprevir)]; Care Dx [Diagnostics (DNA blood test)].
John M Burkart, MD
Section Editor — Dialysis
Professor of Medicine/Nephrology
Wake Forest University Medical Center
Disclosure: Consultant/Advisory Boards: NxStage Medical [Home hemodialysis (Home hemodialysis device)]. Employment: Health Systems Management.
Daniel C Cattran, MD
Professor of Medicine
University of Toronto, Canada
Disclosure: Grant/Research/Clinical Trial Support: Genentech [Membranous nephropathy, FSGS (Rituximab)]. Consultant/Advisory Boards: Mallinckrodt [Membranous nephropathy; focal and segmental glomerulosclerosis (ACTH long-acting gel)]; Omerus [C3G]; Chemocentryx [Vasculitis (C3G)].
Anil Chandraker, MD, FASN, FRCP
Associate Professor of Medicine
Harvard Medical School
Disclosure: Grant/Research/Clinical Trial Support: Alexion [Antibody-mediated rejection (Eculizumab)]. Consultant/Advisory Boards: T2 Biosystems; Dompé; Veloxis [Immunosuppression (Tacrolimus)].
Marc E De Broe, MD, PhD
Emeritus Professor of Medicine
University of Antwerp, Belgium
Disclosure: Nothing to disclose
Bradley M Denker, MD
Associate Professor of Medicine
Harvard Medical School
Disclosure: Nothing to disclose
Joel D Glickman, MD
Professor of Clinical Medicine
University of Pennsylvania School of Medicine
Disclosure: Nothing to disclose
David S Goldfarb, MD, FACP, FASN
Professor of Medicine and Physiology
New York University School of Medicine
Disclosure: Consultant/Advisory Boards: Allena [Nephrolithiasis (Allena 177)]; Retrophin (Cystinuria (Tiopronin)]. Patent Holder: Ravin Group [Nephrolithiasis, cystinuria].
David JA Goldsmith, MA, FRCP
Department of Nephrology and Transplantation
Guy's Hospital, London
Disclosure: Speaker's Bureau: Amgen [CKD-MBD (Cinacalcet)]; Vifor [CKD-MBD (Iron sucrose hydroxyoxide)]; Abbvie [CKD-MBD (Paricalcitol)]; Sanofi [CKD-MBD (Sevelamer)]. Consultant/Advisory Board: Amgen [CKD-MBD (Cinacalcet)]; Vifor [CKD-MBD (Iron sucrose hydroxyoxide)]; Abbvie [CKD-MBD (Paricalcitol)]; Sanofi [CKD-MBD (Sevelamer)].
L Lee Hamm, MD
Professor of Medicine
Tulane University School of Medicine
Disclosure: Nothing to disclose
Karen Hardinger, PharmD, BCPS
Clinical Professor
University of Missouri-Kansas City
Disclosure: Nothing to disclose
Jean L Holley, MD, FACP
Clinical Professor of Medicine
University of Illinois, Urbana-Champaign
Disclosure: Nothing to disclose
Keith Hruska, MD
Ira M Lang Professor of Medicine
Washington University Medical School
Disclosure: Grant/Research/Clinical Trial Support: Celgene [Renal fibrosis, CKD-MBD (Sotatercept)]. Consultant/Advisory Boards: Celgene; Vifor [CKD-MBD (Sucroferric oxyhydroxide)]; Medikine.
Chi-yuan Hsu, MD, MSc
Professor of Medicine
University of California, San Francisco
Disclosure: Nothing to disclose
Ramesh Khanna, MD, FACP
Karl D Nolph, MD Chair in Nephrology, Professor of Medicine
Vice Chair, Department of Medicine
Director, Division of Nephrology
University of Missouri-Columbia
Disclosure: Nothing to disclose
Christina L Klein, MD
Transplant Nephrologist
Piedmont Transplant Institute
Disclosure: Grant/Research/Clinical Trial Support: Astellas [CMV (CMV vaccine)]; Chimerix [CMV (Brincidofovir)]. Speaker's Bureau: Alexion [Atypical HUS (Eculizumab)]. Consultant/Advisory Boards: Alexion [Atypical HUS (Eculizumab)].
Robert G Luke, MD
Taylor Professor of Medicine
University of Cincinnati Medical Center
Disclosure: Nothing to disclose
Orson Moe, MD
Professor of Medicine
UT Southwestern Medical Center at Dallas
Disclosure: Consultant/Advisory Boards: Allena Pharmaceuticals [Hyperoxaluria]; Ardelyx [Hyperphosphatemia].
David B Mount, MD
Assistant Professor of Medicine
Harvard Medical School
Disclosure: Grant/Research/Clinical Trial Support: Ardea [Urate transport (Lesinurad)]. Consultant/Advisory Boards: ZS Pharma [Potassium (ZS9)]; Relypsa [Potassium (Patiromer)].
Mark D Okusa, MD
Professor of Medicine
University of Virginia Health System
Disclosure: Grant/Research/Clinical Trial Support: Coulter Foundation [AKI]; IVY Foundation [AKI]; NIH [AKI]; John Bower Foundation [AKI]; Pfizer [Acute kidney injury (Recombinant alkaline phosphatase)]. Consultant/Advisory Boards: Astellas; [AKI] AM Pharma [AKI]; Merck [AKI]; Mitobridge [AKI]. Patent Holder: B2 pharmaceutical compositions having A2A adenosine receptor agonist activity; Methods and compositions for treating inflammatory response. Equity Ownership/Stock Options: Adenosine Therapeutics [AKI].
Mark Rosenberg, MD
Professor of Medicine
University of Minnesota Medical School
Disclosure: Nothing to disclose
John Vella, MD, FACP, FRCP, FASN
Associate Professor of Medicine
Tufts University School of Medicine
Disclosure: Grant/Research/Clinical Trial Support: Astellas; Bristol Myers Squibb [Transplantation (CMV vaccine, belatacept)].
Anitha Vijayan, MD
Associate Professor of Medicine
Washington University St Louis
Disclosure: Speaker's Bureau: NxSTage [CRRT, AKI (Hemodialysis machine)]; Sanofi [Tumor lysis, AKI (Rasburicase)]. Consultant/Advisory Boards: Baxter [CRRT, AKI (Dialysis machine)]; Abbvie [Hepatitis C treatment (Ombitasvir, paritaprevir, ritonavir, plus dasabuvir)].
Sushrut S Waikar, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Disclosure: Grant/Research/Clinical Trial Support: Genzyme [AKI]; Merck [AKI]; Otsuka [Hyponatremia]; Pfizer [AKI]; Satellite [ESRD]; Biogen [Biomarkers]; Allena [CKD]. Consultant/Advisory Boards: Abbvie [CKD (Endothelin antagonist)]; CVS Caremark [CKD]; Takeda [Hyponatremia (Tolvaptan, febuxostat]; Harvard Clinical Research Institute [CKD (Canagliflozin)]; GSK [HIF stabilizers, biomarkers]; Merck [Biomarkers]; Cerus [design of AKI trials]. Other Financial Interest (Expert Witness): GE Healthcare [ESRD (Gadodiamide)]; Fresenius [ESRD (Dialysis concentrate)]; Pfizer [atorvastatin and diabetes]; Mercury exposure litigation.
Elaine Worcester, MD
Professor of Medicine
University of Chicago
Disclosure: Consultant/Advisory Boards: Allena (product to increase gut metabolism of oxalate).